IU Health is national player in multi-organ transplants
Unusual surgeries bring certain amount of prestige, but not a lot of profit.
Health Care & Life Sciences
Articles
Decatur Vein Clinic branches out
In little more than a decade, former Conseco director Dr. David Decatur has turned his single-office family practice into a multistate chain of vein clinics. A 14th location is planned.
Slabosky retiring from IU Health Plans
Alex Slabosky, who ran the M-Plan HMO for 20 years, is retiring from IU Health and has been replaced by the hospital’s treasurer, Ryan Kitchell.
UnitedHealth to acquire Medicare insurer XLHealth
UnitedHealth Group Inc. said it will acquire XLHealth Corp., a provider of managed care for chronically ill Medicare members. Indianapolis-based WellPoint Inc. had been considering a possible acquisition of the company.
Few employers say they’ll drop health coverage
Few employers in Indiana say they’re likely to drop health benefits after state insurance exchanges are formed in 2014, according to a new survey by the health benefits firm Mercer.
Lilly committed to China despite IP woes
Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.
Potential Lilly drug doubles good cholesterol
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
Cash-strapped Arcadia seeks DailyMed buyer
The Indianapolis-based company is searching for a buyer for its once-promising DailyMed pharmacy service as it struggles to pay $30 million in debt that comes due in April.
Supremes to decide health reform’s fate
After a year of debate followed by a year-and-a-half of recriminations, the fate of President Obama’s health care reform law will come down to a 4-1/2-hour hearing before the U.S. Supreme Court in the spring.
Dumping Amylin ups stakes for Lilly
Eli Lilly and Co. divorced one diabetes darling in favor of a new flame last week, but no analysts cheered. And a few booed.
Potential Effient rival shows promise in study
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
Terre Haute hospital 6th to back Marian med school
Terre Haute’s Union Hospital is investing $100,000 in Marian University’s new College of Osteopathic Medicine.
WellPoint considers bid for managed care firm
XL Health specializes in chronically ill Medicare members, could help WellPoint profits as baby boomers age.
WellPoint eyes $1.5 billion deal for XLHealth
Offers for XLHealth, a provider of managed care for chronically ill Medicare members, may value the company at $1.5 billion to $2 billion.
Riley promotes chief medical officer to CEO
Dr. Jeff Sperring takes the helm after a leadership void created by the departure of Riley’s CEO and COO in late spring.
Lilly files suit over flea medication sales from Australia
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication’s trademark by reselling it to U.S. consumers online.
Cancer-drug firm Endocyte to build commercial team in Indianapolis
Endocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year and a half as it anticipates approval of its ovarian cancer medication in Europe.
Study: IU med school, hospitals boost Indiana economy
A new study says biomedical research at the Indiana University School of Medicine and its partner hospitals pumped about $370 million into Indiana's economy in 2009.
New York orders WellPoint to make refunds for overcharges
WellPoint is among 11 insurers ordered to refund money to almost 600,000 New Yorkers who were charged too much for health insurance.
Lilly, Amylin agree to end diabetes partnership
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.